Compare GSK plc (GSK) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs HSBC Holdings plc — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while HSBC Holdings plc trades at $92.64 (market cap $311.92B). The key difference: HSBC Holdings plc is far larger — about 3.4× GSK plc's market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and HSBC Holdings plc for 36 Days on average.
| GSK | HSBC | |
|---|---|---|
Market Cap | $91.88B | $311.92B |
Volume | 7,730,529 | 3,546,658 |
Sector | Health | Financials |
52-Week High | $61.18 | $107.86 |
52-Week Low | $43.24 | $65.67 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $111.88B | $222.19B |
Dividend Yield | 3.9% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
HSBC trades at $93.71, down 3.97% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and recent earnings beats in two of the last three quarters. Recent developments include expansion in technology banking and wealth management services, while analyst consensus leans toward Hold with 52.38% of ratings.
The outlook remains mixed with strong profitability metrics offset by bearish technical indicators and negative net cash flow. Key opportunities include wealth management growth and strategic hires, while risks involve CFO transition and competitive pressures. The stock's valuation appears reasonable but requires monitoring of cash flow trends and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
